SLICE Study

  • Home
  • SLICE Study Details
  • TREATMENT TRIAL
  • Meet the team
  • Contact Us
  • Publications
  • Home
  • SLICE Study Details
  • TREATMENT TRIAL
  • Meet the team
  • Contact Us
  • Publications

How can YOU help?
Please read below to see if you may be eligible to participate

INDIVIDUALS WITH LYME DISEASE
We are enrolling adults who have been recently diagnosed with Lyme disease.

Eligibility
You may be eligible if you:
  • Are 18 years or older
  • Have a visible erythema migrans rash or rashes 
  • Have been recently diagnosed with carditis, neurologic Lyme disease, Lyme arthritis, or neuropathy AND have a positive Lyme test

Study Information 
This study is not experimental and is not a clinical trial, it is an observational study. 
​
We ask participants to attend 3-5 study visits over the course of one year. These visits will include:
  • Questionnaires and surveys about your health at each visit
  • A physical exam, blood draw, and urine sample at each visit
  • If you have a Lyme disease rash, we will take a 2mm skin biopsy at the site of the rash at your first visit


HEALTHY CONTROLS
We are also seeking healthy control participants, who serve as an invaluable comparison to those with Lyme disease. 

Eligibility
You may be eligible if you:
  • Are 18 years or older
  • Have no prior history of Lyme disease or Lyme vaccine
  • Are generally in good health 

Study Information
This study is not experimental and is not a clinical trial, it is an observational study. 

​We ask controls to attend one initial screening visit and two study visits over the course of six months. These visits will include:
  • Questionnaires and surveys about your health at each visit
  • A physical exam, blood draw and urine sample at each visit

    How to contact us:

    Feel free to call us at ​(410) 870-5963
    OR fill out the form below

Submit
Picture
Courtesy: CDC/ James Gathany, William L. Nicholson, Ph.D.
Picture
Courtesy: flic.kr user polandeze https://www.flickr.com/photos/polandeze/
Principal Investigator: John Aucott, MD                                                                                                                              
IRB Protocol IRB00272446; IRB00288079
© 2016